Ultrastructural evaluation of an endomyocardial biopsy can be used to evaluate the severity of myocyte damage following doxorubicin therapy. Patients with moderate to severe damage are at risk for congestive cardiomyopathy and should not receive additional chemotherapy with doxorubicin.